|
Title
|
|
|
|
Primary IgA-mediated autoimmune hemolytic anemia in an infant successfully treated with rituximab
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Autoimmune hemolytic anemia (AIHA) is uncommon in the pediatric population and is often associated with an infectious etiology or postvaccination. Mostly, the child presents with a positive direct antiglobulin test. The diagnosis can be challenging, as in our case with an immunoglobulin A-mediated AIHA. In addition to supportive therapy, such as a red blood cell transfusion, steroids are the first choice of treatment. Rituximab, as second-line treatment, can be given in conjunction. We report the first case of immunoglobulin A-mediated AIHA treated with rituximab in the literature. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Journal of pediatric hematology, oncology. - New York
|
|
|
Publication
|
|
|
|
New York
:
2020
|
|
|
ISSN
|
|
|
|
1077-4114
|
|
|
DOI
|
|
|
|
10.1097/MPH.0000000000001765
|
|
|
Volume/pages
|
|
|
|
42
:7
(2020)
, p. E615-E619
|
|
|
ISI
|
|
|
|
000576514200024
|
|
|
Pubmed ID
|
|
|
|
32118812
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|